Immune effector target

The term Immune effector target is a generic functional classification rather than a specific, unique molecular entity or receptor. In immunology and oncology, it typically refers to any molecule (often a cell-surface antigen) expressed on a pathological cell that is recognized and attacked by immune effector cells, such as cytotoxic T lymphocytes (CTLs) or natural killer (NK) cells. Common examples of specific molecules that fall under this broad category include CD19 in B-cell malignancies, BCMA in multiple myeloma, or HER2 in solid tumors. Because the term does not identify a single protein, enzyme, or receptor, it cannot be characterized by a single set of biochemical properties or a specific mechanism of action. In the context of drug development, therapeutic strategies like CAR-T cell therapy, bispecific T-cell engagers (BiTEs), and antibody-dependent cellular cytotoxicity (ADCC) are designed to bridge immune effector cells to these targets to facilitate programmed cell death. Due to its lack of specificity, this entry is considered incorrect for structured pharmacological data entry which requires a defined gene or protein product.

Other names

Immune effector cell targetEffector cell target

Not applicable as this is a generic category rather than a specific molecular target.